Discover the highlights of SpectraCure’s 2024 half year report!
Listen when Dr. Masoud Khayyami, former CEO of SpectraCure, comments on the report for the second quarter, with Erika Eliasson Ekberger as moderator.
SpectraCure is developing the future systems for the treatment of internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. When prostate cancer recurs, there are often no established treatment options other than lifelong hormone therapy, with its associated side effects.